Artelo Biosciences, Inc. (ARTL)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Artelo Biosciences, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Artelo Biosciences, Inc. (ARTL) has returned 107.10% so far this year and -51.87% over the past 12 months.

Based on dividend-adjusted daily data since Nov 14, 2017, ARTL's average daily return is +0.29%, while the average monthly return is +2.20%. At this rate, your investment would double in approximately 2.7 years.

Historically, 40% of months were positive and 60% were negative. The best month was Jun 2019 with a return of +318.2%, while the worst month was Oct 2020 at -53.9%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 12 months.

On a daily basis, ARTL closed higher 44% of trading days. The best single day was Jun 21, 2019 with a return of +284.3%, while the worst single day was Sep 4, 2025 at -50.3%.

Artelo Biosciences, Inc. has an annualized alpha of 88.58%, beta of 0.64, and R² of 0.00 versus S&P 500 Index. Calculated based on daily prices since November 15, 2017.

• This stock participated in 191.31% of S&P 500 Index downside but only 18.77% of its upside — more exposed to losses than it benefited from rallies.
• Beta of 0.64 may look defensive, but with R² of 0.00 this stock is largely uncorrelated with S&P 500 Index — low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R² of 0.00 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

ARTL ranks 45 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.

The table below present risk-adjusted performance metrics for Artelo Biosciences, Inc. (ARTL) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Artelo Biosciences, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Artelo Biosciences, Inc. was 99.76%, occurring on Mar 26, 2026. The portfolio has not yet recovered.

The current Artelo Biosciences, Inc. drawdown is 99.43%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Artelo Biosciences, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Artelo Biosciences, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.